Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$53.54 USD

53.54
4,030,866

-1.09 (-2.00%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $54.00 +0.46 (0.86%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

by Zacks Equity Research

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Company News for Sep 13, 2024

by Zacks Equity Research

Companies in The News Are: KR,SIG,ALK,MRNA

Kinjel Shah headshot

Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?

by Kinjel Shah

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

by Zacks Equity Research

The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.

Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years

by Zacks Equity Research

The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.

Sundeep Ganoria headshot

FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs

by Sundeep Ganoria

On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.

Kinjel Shah headshot

Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More

by Kinjel Shah

LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.

Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters

by Zacks Equity Research

Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.

Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.

Pfizer (PFE) Touts RSV Jab Benefit in Immunocompromised Adults

by Zacks Equity Research

Results from a late-stage study show that Pfizer's (PFE) RSV vaccine generated strong neutralizing responses in immunocompromised adults after receiving a single dose.

The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna

by Zacks Equity Research

Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.

Kinjel Shah headshot

Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip

by Kinjel Shah

Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Sundeep Ganoria headshot

Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.

Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 4.03% and 92.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

by Ekta Bagri

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

by Zacks Equity Research

Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.

Ahan Chakraborty headshot

Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Ahan Chakraborty

Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Ekta Bagri headshot

5 Biotech Stocks to Bet On Bright Industry Prospects

by Ekta Bagri

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Sundeep Ganoria headshot

Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.